Krishnan Mahesh

Halozyme Therapeutics, Inc. · Director

Krishnan Mahesh serves as a Director at Halozyme Therapeutics, Inc., a company known for its innovations in the healthcare sector. His trading activity is documented through SEC Form 4 filings, revealing a focus on sale transactions. Between May 2, 2025, and June 30, 2026, Mahesh reported six disclosures, all related to Halozyme Therapeutics (ticker: HALO), with the largest sale valued at $547.8K.

History Trades

CompanyValueActionPriceCurrent Price
Historical insider buys and sells before the latest disclosure date will appear here after more snapshots are available.